AstraZeneca said it has started to disclose payments and other “transfers of value” made to physicians and healthcare organizations, including hospitals, in the U.S.
AstraZeneca disclosing payments to docs, healthcare organizations
The pharmaceutical company is disclosing consulting and speaker fees, meals and travel, educational items, pre-clinical or clinical research payments, royalties, license fees, and ownership or investments interests, according to a post on the drugmaker's blog.
The searchable database also lists payments paid to physicians through third parties and payments made to medical and research institutions, hospitals, clinics and group practices.
AstraZeneca began reporting speaker's program fees that were paid to physicians in the U.S. in 2010.
The disclosure was later incorporated into the corporate integrity agreement that AstraZeneca signed with HHS' inspector general's office in 2010, according to information posted on the pharmaceutical company's website. AstraZeneca had agreed in 2010 to pay $520 million to settle allegations that it illegally marketed its antipsychotic drug Seroquel.
“We announced in May 2008 that we supported the disclosure of payments to physicians through the Sunshine Act,” said AstraZeneca spokesperson Tony Jewell in an e-mail. “It was subsequently included in the healthcare reform legislation and our corporate integrity agreement.”
Eli Lilly and Co., an Indianapolis-based pharmaceutical company, launched a physician payment registry in July. The registry is also required by a corporate integrity agreement, according to a news release.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.